A live Q&A stream from DOWNSIZED taking viewer questions about GLP-1 medications, including Zepbound, Wegovy and Foundayo.
Recap by typeshit. Full story at DOWNSIZED.
BMO's Evan Seigerman expects US share losses to weigh on Ozempic sales, while the 25% CagriSema figure comes from a post-hoc subgroup, not the full trial's 22.7%.
Beauty companies are reportedly exploring products aimed at facial changes linked to rapid weight loss on GLP-1 drugs.
A search page for retatrutide news with no specific story attached, so there is little new beyond recent coverage.
A link to a betting market on whether Lilly's retatrutide gets FDA approval, with no reporting or detail on the drug's actual status.
Bhekisisa reports illegal weight loss injections are still on sale, and the new rules meant to curb the trade are still months off.
Penn researchers stress the self-reports in JAMA Network Open don't prove the drug caused anything, but increased appetite topped the list despite trials pointing to nausea.
Loading…